nivolumab
Nivolumab is a drug used to treat Melanoma, Renal Cell Carcinoma, Metastatic Melanoma, and other conditions. Nivolumab is being actively studied in 633 studies and prior, has been studied in 112.
Top Sponsors | Top Sites | Top Investigators |
---|---|---|
Bristol-Myers Squibb | Local Institution | Ivan S Moiseev |
National Cancer Institute (NCI) | Memorial Sloan Kettering Cancer Center | Inna Chen, MD |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Dana Farber Cancer Institute | Theodore Sunki Hong |
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
A
Recruiting
- Melanoma Stage III
- Melanoma
- nivolumab
- Ipilimumab
- Durham, North Carolina
- +1 more
2022-03-25
Mar 25, 2022D
Recruiting
- Melanoma
- Vidutolimod (CMP-001)
- +2 more
- Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
2022-03-25
Mar 25, 2022I
Recruiting
- Muscle-Invasive Bladder Carcinoma
- Nivolumab + Nab-paclitaxel
- Nivolumab
- Milan, MI, ItalyGenitourinary Medical Oncology - IRCCS San Raffaele Hospital and
2022-03-28
Mar 28, 2022B
Not yet recruiting
- Squamous Cell Carcinoma of Head and Neck
- Combination 5-azacytidine and nivolumab
- +2 more
- (no location specified)
2022-03-29
Mar 29, 2022D
Recruiting
- NSCLC
- +2 more
- Pixatimod
- +2 more
- Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
2022-03-28
Mar 28, 2022C
Not yet recruiting
- Gastric Cancer
- Chemotherapy Effect
- Nivolumab plus SOX
- +2 more
- (no location specified)
2022-01-07
Jan 7, 2022C
Recruiting
- Recurrent Classic Hodgkin Lymphoma
- Refractory Classic Hodgkin Lymphoma
- Nivolumab
- Oral Azacitidine
- Duarte, CaliforniaCity of Hope Medical Center
2022-02-28
Feb 28, 2022B
Completed
- Solid Tumors
- Nivolumab
- Guangzhou, Guangdong, China
- +1 more
2022-03-14
Mar 14, 2022Y
Recruiting
- Recurrent/Metastatic Carcinosarcoma
- nivolumab
- Seoul, Korea, Republic ofSeverance Hospital, Yonsei University Health System
2022-02-03
Feb 3, 2022N
Active, not recruiting
- Ann Arbor Stage III Lymphoma
- +4 more
- Copanlisib
- +2 more
- Bethesda, Maryland
- +2 more
2022-04-05
Apr 5, 2022D
Recruiting
- Melanoma
- Metastatic Melanoma
- CDX-301
- +2 more
- Boston, MassachusettsDana-Farber Cancer Institute
2022-03-16
Mar 16, 2022S
Active, not recruiting
- Neuroendocrine Tumors
- Carcinoid Tumor
- Nivolumab
- Ipilimumab
- Baltimore, MarylandJohns Hopkins Medical Institution
2021-12-15
Dec 15, 2021T
D
Active, not recruiting
- Thyroid Cancer
- Nivolumab
- Ipilimumab
- Boston, MassachusettsDana Farber Cancer Institute
2022-02-18
Feb 18, 2022S
Recruiting
- Microsatellite Stable (MSS) Colorectal Adenocarcinomas
- Colorectal Adenocarcinoma
- Nivolumab
- Relatlimab
- Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
2022-03-14
Mar 14, 2022R
Active, not recruiting
- Renal Cell Carcinoma
- Entinostat
- +2 more
- Washington, District of Columbia
- +1 more
2022-01-10
Jan 10, 2022S
Recruiting
- Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy
- MSI-H Tumors
- Nivolumab
- Relatlimab
- Baltimore, MarylandSidney Kimmel Comprehensive Cancer Center
2022-03-14
Mar 14, 2022D
Active, not recruiting
- Squamous Cell Carcinoma of the Head and Neck
- Nivolumab
- Lirilumab
- Boston, MassachusettsDana-Farber Cancer Institute
2021-07-22
Jul 22, 2021S
Recruiting
- Multiple Myeloma
- Melphalan
- +2 more
- Saint Petersburg, Russian FederationBoris V Afanasyev, MD, Prof.
2022-04-04
Apr 4, 2022A
Recruiting
- Metastatic Melanoma
- Hypofractionated Radiation Therapy (HFRT)
- +2 more
- Lancaster, Pennsylvania
- +1 more
2022-03-30
Mar 30, 2022T
Active, not recruiting
- Breast Cancer
- Nivolumab
- +4 more
- Amsterdam, NetherlandsAntoni van Leeuwenhoek
2022-03-21
Mar 21, 2022I
Recruiting
- Metastatic Melanoma
- Nivolumab
- PD-L1/IDO peptide vaccine
- Herlev, Denmark
- +1 more
2022-03-15
Mar 15, 2022N
Suspended
- Acute Myeloid Leukemia
- Decitabine
- +2 more
- Columbus, OhioOhio State University Comprehensive Cancer Center
2022-04-05
Apr 5, 2022A
Active, not recruiting
- Oral Cavity Squamous Cell Carcinoma
- Nivolumab
- Amsterdam, Noord-Holland, NetherlandsVU University medical center
2021-10-06
Oct 6, 2021S
Recruiting
- Nasopharyngeal Carcinoma
- Nivolumab
- +2 more
- San Francisco, California
- +1 more
2022-02-07
Feb 7, 2022